Epstein Secrets

worldwide." "We are grateful to the thousands of patients and investigators worldwide who participated in the ODYSSEY clinical trial program," said Leonard S. Schleifer, M., Founder, President, and Chief Executive Officer, Regeneron. "Praluent represents the culmination of more than a decade of tireless work to tra

ainst heart disease — and the approval is a triumph for Regeneron Pharmaceuticals, the Tarrytown, N.Y.-based biotechnology company that invented it. Praluent is likely to be more widely used, and to cost more, than Wall Steet analysts expected. That also means it could be a big cost down the line. "Obvi

low me on Twitter, circle me onGoogle Plus, or subscribe to my Facebook page. Loading... Loading... The Food and Drug Administration has approved Praluent, a new medicine to lower cholesterol in people who have established heart disease, for people whose risk of a heart attack or stroke is not being ad

had heart attacks or strokes, who are already taking the maximum dose of a statin they can tolerate. Regeneron and its marketing partner Sanofi say Praluent will have a wholesale cost of $40 a day, or $14,600 a year, for either of two doses, 75 milligrams or 150 mgs. It’s likely that insurance companies w

worldwide." "We are grateful to the thousands of patients and investigators worldwide who participated in the ODYSSEY clinical trial program," said Leonard S. Schleifer, M.D., Ph.D., Founder, President, and Chief Executive Officer, Regeneron. "Praluent represents the culmination of more than a decade of tireless work

had heart attacks or strokes, who are already taking the maximum dose of a statin they can tolerate. Regeneron and its marketing partner Sanofi say Praluent will have a wholesale cost of $40 a day, or $14,600 a year, for either of two doses, 75 milligrams or 150 mgs. It’s likely that insurance companies w

worldwide." "We are grateful to the thousands of patients and investigators worldwide who participated in the ODYSSEY clinical trial program," said Leonard S. Schleifer, M.D., Ph.D., Founder, President, and Chief Executive HOUSE_OVERSIGHT_026364 --- PAGE BREAK --- Officer, Regeneron. "Praluent represents the culmi